abc trials joint analysis tc high-risk her2 negative early breast cancerABC试验联合分析TCvstaxac在高风险阴性早期乳腺癌中.pptx

下载文档

1
0
约6.25千字
约 12页
2025-03-11 发布于北京
举报
版权申诉
保障服务

abc trials joint analysis tc high-risk her2 negative early breast cancerABC试验联合分析TCvstaxac在高风险阴性早期乳腺癌中.pptx

1、本文档共12页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。

CCOIndependentConferenceCoverage*

ofthe2016ASCOAnnualMeeting,June3-7,2016ABCTrialsJointAnalysis:

TCvsTaxACinHigh-Risk,

HER2-NegativeEarlyBreastCancer*CCOisanindependentmedicaleducationcompanythatprovidesstate-of-the-artmedicalinformationtohealthcareprofessionalsthroughconferencecoverageandothereducationalprograms.ThisactivityissupportedbyeducationalgrantsfromAmgen,Ariad,

BayerHealthcarePharmaceuticals,CelgeneCorporation,Genentech,Incyte,Merck,andTaihoPharmaceuticals.

ABCJointAnalysisofTCvsTaxACinHER2-BreastCancer:Background2011EBCTCGmeta-analysis[1]10-yrBCmortalitysimilarwithstddosesofanthracyclines;reducedwithhighercumulativedosesofanthracyclinesvsCMF8-yrBCmortalityfurtherreducedbyaddingtaxanestoanthracyclines(TaxAC)10-yrBCmortalityreducedby1/3withTaxACvsnochemotherapyCardiacmortalityincreasedwithanthracyclinesvsCMFornilUSORtrialshowedsuperiorOSforTCvsAC(HR:0.69;

P=.032)[2]Pooledanalysisundertakentodetermineif6cyclesofTCisnoninferiortoTaxACinwomenwithresected,high-risk,HER2-negativebreastcancer[3]1.EBCTCG,etal.Lancet.2012;379:432-444.2.JonesS,etal.JClinOncol.2009;27:1177-1183.3.BlumJL,etal.ASCO2016.Abstract1000.Slidecredit:

TCvsTaxACinHER2-BreastCancer

(ABCJointAnalysis):Timeline,Accrual,TxDatafrom3clinicaltrialsofanthracyclinesinearlybreastcancer(ABCtrials)prospectivelypooledforanalysisPtsreceivedsamegeneralregimensacrosstrialsTaxACarms:concurrentTACorsequentialACfollowedbypaclitaxel(onlyinNSABPB-49)Otherarms:TCER+orPgR+pts:≥5yrsendocrinetherapyBlumJL,etal.ASCO2016.Abstract1000.Slidecredit:TrialAccrual,nDatesofAccrualMedianFollow-up,YrsUSOR06-0901295May2007-June20096.3NASBPB-461USOR071321077May2009-Jan20124.8NSABPB-491870April2012-Nov20132.2

TCvsTaxACinHER2-BreastCancer:EligibilityCriteri